铂生卓越生物科技干细胞疗法艾米迈托赛获批上市近日,NMPA 官网显示,铂生卓越生物科技(北京)有限公司的干细胞疗法“艾米迈托赛”获批上市,用于治疗 14 岁以上消化道受累为主的激素治疗失败的急性移植物抗宿主病。这是国内首款获批上市的干细胞疗法。据悉,艾米迈托赛是一款间充质干细胞疗法(MSC)。该药早在 2013 年 3 月就在国内递交了 IND 申请,但直至 2020 年 6 月才首次公示临床试验...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.